Isabl
YC W20 ↗New York City, US · Founded 2020 · 5 employees · 3 known investors
Isabl develops whole genome and transcriptome sequencing technology for cancer diagnosis, delivering comprehensive genomic profiling and treatment options to physicians and research teams. The company provides rapid cancer diagnostic tests in clinically relevant timeframes to improve outcomes for cancer patients globally.
